Alembic Pharma’s API-III Facility Gets Clean Chit from USFDA—No Observations, Full Compliance

Alembic Pharmaceuticals Ltd. has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API-III manufacturing facility in Karakhadi, Gujarat, confirming the successful completion of a Good Manufacturing Practices (GMP) inspection with zero Form 483 observations. The inspection, conducted between March 17–21, 2025, validates the site’s adherence to stringent US regulatory standards and boosts Alembic’s compliance credentials in the global API market.

 

This development is expected to enhance Alembic’s export momentum, particularly in regulated markets like the US, and reinforces investor confidence amid a challenging earnings cycle.

 

Key Highlights:

This clean EIR comes at a crucial time as Alembic ramps up its API exports and filings in the US and EU markets.

 

Source: Bajaj Broking | Economic Times Company Updates